<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study investigates the influence on <z:chebi fb="1" ids="9754">tromethamine</z:chebi> (<z:chebi fb="0" ids="9754">THAM</z:chebi>) on ischemic volume induced by permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in rats </plain></SENT>
<SENT sid="1" pm="."><plain>14 male Sprague Dawley rats underwent left sided permanent MCAO by electro coagulation </plain></SENT>
<SENT sid="2" pm="."><plain>Animals were treated either by 3-M <z:chebi fb="0" ids="9754">THAM</z:chebi> given intravenously in a single dosage of 0.6 mmol/kg body weight (<z:chebi fb="0" ids="9754">THAM</z:chebi> group: n = 7) 10 min following MCAO and again 1, 2, 3, 4 and 5 hours later or by <z:chebi fb="1" ids="26710">NaCl</z:chebi> 0.9% (placebo group: n = 7) in the same mode </plain></SENT>
<SENT sid="3" pm="."><plain>Mean arterial blood pressure (MABP) was monitored for 30 min post MCAO and arterial blood gases were taken 10 min after the first injection </plain></SENT>
<SENT sid="4" pm="."><plain>The extent of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> volume was assessed by planimetry of coronal sections stained with triphenyl-tetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) and with hematoxilin/eosin (HE) </plain></SENT>
<SENT sid="5" pm="."><plain>Tests for significance were accomplished by ANOVA on ranks </plain></SENT>
<SENT sid="6" pm="."><plain>A difference of p &lt; 0.05 was considered significant </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:chebi fb="0" ids="9754">THAM</z:chebi> group showed an insignificant decrease in MABP 1 min after injection (<z:chebi fb="0" ids="9754">THAM</z:chebi>: 75 +/- 11 mmHg, placebo: 86 +/- 10 mmHg) </plain></SENT>
<SENT sid="8" pm="."><plain>Arterial pH was significantly different (<z:chebi fb="0" ids="9754">THAM</z:chebi>: 7.46 +/- 0.04; placebo: 7.32 +/- 0.03) </plain></SENT>
<SENT sid="9" pm="."><plain>In TTC staining, the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> volume--given in absolute values and percentage of the total left volume--was significantly reduced in the <z:chebi fb="0" ids="9754">THAM</z:chebi> group (<z:chebi fb="0" ids="9754">THAM</z:chebi>: 43.9 +/- 8.3 mm3/7.0 +/- 1.3%; placebo: 95.2 +/- 13.8 mm3/14.2 +/- 2.0%) </plain></SENT>
<SENT sid="10" pm="."><plain>In HE staining, the reduction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, volume did not reach statistical significance (<z:chebi fb="0" ids="9754">THAM</z:chebi>: 49.1 +/- 9.9 mm3/9.6 +/- 1.8%; placebo: 66.3 +/- 14.5 mm3/13.1 +/- 2.8%) </plain></SENT>
<SENT sid="11" pm="."><plain>Based on these results, a moderate neuroprotective effect of <z:chebi fb="0" ids="9754">THAM</z:chebi> in experimental <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> could be demonstrated </plain></SENT>
</text></document>